The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://larissavbgf784169.ja-blog.com/39064815/retatrutide-vs-tirzepatide-a-comparative-analysis